166 related articles for article (PubMed ID: 22211090)
1. The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist.
Patel K; Dixit VD; Lee JH; Kim JW; Schaffer EM; Nguyen D; Taub DD
Int J Med Sci; 2012; 9(1):51-8. PubMed ID: 22211090
[TBL] [Abstract][Full Text] [Related]
2. Identification of ghrelin receptor blocker, D-[Lys3] GHRP-6 as a CXCR4 receptor antagonist.
Patel K; Dixit VD; Lee JH; Kim JW; Schaffer EM; Nguyen D; Taub DD
Int J Biol Sci; 2012; 8(1):108-17. PubMed ID: 22211109
[TBL] [Abstract][Full Text] [Related]
3. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.
Wu L; LaRosa G; Kassam N; Gordon CJ; Heath H; Ruffing N; Chen H; Humblias J; Samson M; Parmentier M; Moore JP; Mackay CR
J Exp Med; 1997 Oct; 186(8):1373-81. PubMed ID: 9334377
[TBL] [Abstract][Full Text] [Related]
4. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
5. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells.
Longden J; Cooke EL; Hill SJ
Br J Pharmacol; 2008 Apr; 153(7):1513-27. PubMed ID: 18223665
[TBL] [Abstract][Full Text] [Related]
6. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with the ghrelin receptor antagonist [d-Lys3]-GHRP-6 does not improve glucose homeostasis in nonobese diabetic MKR mice.
Mosa R; Huang L; Li H; Grist M; LeRoith D; Chen C
Am J Physiol Regul Integr Comp Physiol; 2018 Jan; 314(1):R71-R83. PubMed ID: 28903914
[TBL] [Abstract][Full Text] [Related]
8. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
Scarlatti G; Tresoldi E; Björndal A; Fredriksson R; Colognesi C; Deng HK; Malnati MS; Plebani A; Siccardi AG; Littman DR; Fenyö EM; Lusso P
Nat Med; 1997 Nov; 3(11):1259-65. PubMed ID: 9359702
[TBL] [Abstract][Full Text] [Related]
9. Preferential HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of CCR5 ligands.
Alvarez Y; Tuen M; Shen G; Nawaz F; Arthos J; Wolff MJ; Poles MA; Hioe CE
J Virol; 2013 Oct; 87(19):10843-54. PubMed ID: 23903844
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
Xiang J; George SL; Wünschmann S; Chang Q; Klinzman D; Stapleton JT
Lancet; 2004 Jun; 363(9426):2040-6. PubMed ID: 15207954
[TBL] [Abstract][Full Text] [Related]
11. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
Maeda Y; Foda M; Matsushita S; Harada S
J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
[TBL] [Abstract][Full Text] [Related]
12. Aminooxypentane addition to the chemokine macrophage inflammatory protein-1alpha P increases receptor affinities and HIV inhibition.
Townson JR; Graham GJ; Landau NR; Rasala B; Nibbs RJ
J Biol Chem; 2000 Dec; 275(50):39254-61. PubMed ID: 11005816
[TBL] [Abstract][Full Text] [Related]
13. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.
Nibbs RJ; Yang J; Landau NR; Mao JH; Graham GJ
J Biol Chem; 1999 Jun; 274(25):17478-83. PubMed ID: 10364178
[TBL] [Abstract][Full Text] [Related]
14. Limited expression of R5-tropic HIV-1 in CCR5-positive type 1-polarized T cells explained by their ability to produce RANTES, MIP-1alpha, and MIP-1beta.
Annunziato F; Galli G; Nappi F; Cosmi L; Manetti R; Maggi E; Ensoli B; Romagnani S
Blood; 2000 Feb; 95(4):1167-74. PubMed ID: 10666186
[TBL] [Abstract][Full Text] [Related]
15. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy.
Pierdominici M; Giovannetti A; Ensoli F; Mazzetta F; Marziali M; De Cristofaro MR; Santini-Muratori D; Leti W; Aiuti F
J Acquir Immune Defic Syndr; 2002 Feb; 29(2):122-31. PubMed ID: 11832680
[TBL] [Abstract][Full Text] [Related]
16. Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of β-chemokines.
Tanaka R; Takahashi Y; Kodama A; Saito M; Ansari AA; Tanaka Y
AIDS Res Hum Retroviruses; 2010 Oct; 26(10):1147-54. PubMed ID: 20854204
[TBL] [Abstract][Full Text] [Related]
17. G-protein-coupled receptor screen reveals a role for chemokine receptor CCR5 in suppressing microglial neurotoxicity.
Gamo K; Kiryu-Seo S; Konishi H; Aoki S; Matsushima K; Wada K; Kiyama H
J Neurosci; 2008 Nov; 28(46):11980-8. PubMed ID: 19005063
[TBL] [Abstract][Full Text] [Related]
18. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.
Blanpain C; Doranz BJ; Bondue A; Govaerts C; De Leener A; Vassart G; Doms RW; Proudfoot A; Parmentier M
J Biol Chem; 2003 Feb; 278(7):5179-87. PubMed ID: 12466283
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of M-tropic HIV-1 infection by the fd phage-gene 3 protein with MIP-1alpha-binding activity.
Meta A; Torigoe N; Ito Y; Arakaki R; Nakashima H; Sugimura K
Mol Immunol; 1999 Dec; 36(18):1249-54. PubMed ID: 10684964
[TBL] [Abstract][Full Text] [Related]
20. I-TAC/CXCL11 is a natural antagonist for CCR5.
Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
